Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
Stutterheim J, de Lorenzo P, van der Sluis IM, Alten J, Ancliffe P, Attarbaschi A, Aversa L, Boer JM, Biondi A, Brethon B, Diaz P, Cazzaniga G, Escherich G, Ferster A, Kotecha RS, Lausen B, Leung AW, Locatelli F, Silverman L, Stary J, Szczepanski T, van der Velden VHJ, Vora A, Zuna J, Schrappe M, Valsecchi MG, Pieters R. Stutterheim J, et al. Among authors: escherich g. Eur J Cancer. 2022 Jan;160:72-79. doi: 10.1016/j.ejca.2021.10.004. Epub 2021 Nov 13. Eur J Cancer. 2022. PMID: 34785111 Free article.
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.
Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R. Driessen EM, et al. Among authors: escherich g. Leukemia. 2016 May;30(5):1184-7. doi: 10.1038/leu.2015.246. Epub 2015 Sep 15. Leukemia. 2016. PMID: 26369984 No abstract available.
Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin JP, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A. Eckert C, et al. Among authors: escherich g. Leukemia. 2015 Aug;29(8):1648-55. doi: 10.1038/leu.2015.59. Epub 2015 Mar 9. Leukemia. 2015. PMID: 25748682
RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
Jerchel IS, Hoogkamer AQ, Ariës IM, Steeghs EMP, Boer JM, Besselink NJM, Boeree A, van de Ven C, de Groot-Kruseman HA, de Haas V, Horstmann MA, Escherich G, Zwaan CM, Cuppen E, Koudijs MJ, Pieters R, den Boer ML. Jerchel IS, et al. Among authors: escherich g. Leukemia. 2018 Apr;32(4):931-940. doi: 10.1038/leu.2017.303. Epub 2017 Oct 3. Leukemia. 2018. PMID: 28972594 Free PMC article.
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.
Driessen EMC, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R. Driessen EMC, et al. Among authors: escherich g. Leukemia. 2017 Dec;31(12):2854. doi: 10.1038/leu.2017.279. Leukemia. 2017. PMID: 29210366
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.
Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, Van Zutven LJ, Beverloo HB, Van der Spek PJ, Escherich G, Horstmann MA, Janka-Schaub GE, Kamps WA, Evans WE, Pieters R. Den Boer ML, et al. Among authors: escherich g. Lancet Oncol. 2009 Feb;10(2):125-34. doi: 10.1016/S1470-2045(08)70339-5. Epub 2009 Jan 8. Lancet Oncol. 2009. PMID: 19138562 Free PMC article.
Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia.
van der Veer A, van der Velden VH, Willemse ME, Hoogeveen PG, Petricoin EF, Beverloo HB, Escherich G, Horstmann MA, Pieters R, den Boer ML. van der Veer A, et al. Among authors: escherich g. Blood Cancer J. 2014 Feb 14;4(2):e181. doi: 10.1038/bcj.2014.5. Blood Cancer J. 2014. PMID: 24531445 Free PMC article. No abstract available.
175 results